Latest Administration News

Radiopharm Theranostics reports promising second interim Phase 2b results for RAD 101, showing 90% concordance with MRI in detecting brain metastases and encouraging sensitivity and specificity trends.

Echo IQ has strengthened its partnership with Mayo Clinic to distribute its AI-driven heart failure diagnostic tool, EchoSolv HF, pending FDA clearance. The expanded agreement offers a scalable commercial pathway across a vast US hospital network.

SQX Resources has addressed an ASX compliance query regarding director Bevan Tarratt’s trading during a closed period, confirming prior board approval and an administrative disclosure error.

Generation Development Group Limited updates its Dividend Reinvestment Plan price to AUD 3.86 per share for the upcoming fully franked dividend, signalling steady shareholder returns for the half-year ending December 2025.

Sequoia Financial Group has agreed to sell its financial planning arm InterPrac to Conquest Investment Partners for $50,000, following a strategic review that exposed significant challenges and asset write-downs.

Nexsen Limited has successfully completed a pivotal FDA Pre-Submission meeting for its StrepSure® diagnostic, significantly reducing regulatory risks and advancing its entry into the large US maternal health market.

Lindian Resources has operationalised its Tipume Accommodation Camp at the Kangankunde Rare Earths Project, enabling workforce expansion and accelerating construction towards first production in late 2026.

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

Ragnar Metals has confirmed high-grade gold extensions at its Harnäs Project in Sweden through recent channel and rock sampling, with drilling preparations now underway following regulatory approvals.

Merino & Co. Limited has attributed the late lodgement of director interest notices to an administrative oversight and reaffirmed its compliance measures to meet ASX disclosure rules.

Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.

Horizon Oil has released a first supplementary and replacement bidder’s statement for its off-market takeover offer for Cue Energy, proposing a mix of cash and shares that values Cue at a 10-14% premium. The deal aims to create a diversified oil and gas producer across Asia-Pacific with significant synergies.